Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Initial Phase I Clinical Trial to Evaluate a Prophylactic Breast Cancer Vaccine in Women Diagnosed with High-Risk Early Stage Triple-Negative Breast Cancer (TNBC)

X
Trial Profile

An Initial Phase I Clinical Trial to Evaluate a Prophylactic Breast Cancer Vaccine in Women Diagnosed with High-Risk Early Stage Triple-Negative Breast Cancer (TNBC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Breast cancer vaccine-Anixa Biosciences/Cleveland Clinic (Primary)
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Mar 2024 According to an Anixa Biosciences media release, positive interim results from the Phase 1 clinical trial of Anixa's breast cancer vaccine will be presented at the 24th Annual World Vaccine Congress being held April 1-4, 2024.
    • 06 Dec 2023 According to an Anixa Biosciences media release, data from this study will be presented today at 2023 San Antonio Breast Cancer Symposium.
    • 06 Dec 2023 According to an Anixa Biosciences Media Release, data from this study were presented at the 2023 San Antonio Breast Cancer Symposium by G. Thomas Budd, M.D.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top